RA
NUTX

Rise Advisors’s Nutex Health NUTX Stock Holding History

Rise Advisors’s Portfolio NUTX Stock Details NUTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-11
Closed -$1.37K – 1582
2025
Q2 		$1.37K Buy
+11
New +$1.42K ﹤0.01% 1239

Other funds holding NUTX

TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
PP
Pertento Partners London, United Kingdom $1.37B AUM 36.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Rise Advisors's NUTX Position: Q3 2025 in Review

Rise Advisors sold out of Nutex Health (NUTX) in Q3 2025, closing a stake of 11 shares — an estimated $1.37K sold.

Rise Advisors first reported a position in NUTX in Q2 2025 and held it in 1 quarter. The position peaked at $1.37K in Q2 2025. 95 funds tracked by Wall St. Rank hold NUTX as of Q3 2025.

  • Rise Advisors reported no remaining Nutex Health position as of Q3 2025 after selling out during the quarter.
  • Rise Advisors sold 11 Nutex Health shares in Q3 2025, an estimated $1.37K.
  • Rise Advisors first reported a position in Nutex Health in Q2 2025 and held it in 1 quarter.
  • Rise Advisors's Nutex Health position peaked at $1.37K in Q2 2025.
  • 95 funds tracked by Wall St. Rank held Nutex Health as of Q3 2025.

Based on Rise Advisors's 13F filing for Q3 2025, filed 8 Oct 2025.